Reference health
Ivabradine
62/62 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 62 checked references that resolve
resolves10.7326/0003-4819-150-11-200906020-00006
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
resolves10.1016/j.amjcard.2007.11.023
Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers
resolves10.1161/JAHA.113.000668
Long‐term Cardiovascular Risks Associated With an Elevated Heart Rate: The Framingham Heart Study
resolves10.1016/j.jacc.2013.11.027
Resting Heart Rate as Predictor for Left Ventricular Dysfunction and Heart Failure
resolves10.1161/JAHA.114.001626
Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization
resolves10.1016/j.jchf.2013.08.005
The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm
resolves10.1093/eurheartj/ehs004
Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure
resolves10.1016/j.cardfail.2010.04.013
Heart Rate Predicts Mortality in Patients With Heart Failure and Preserved Systolic Function
resolves10.1016/S0140-6736(08)61171-X
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
resolves10.1016/j.ahj.2013.01.007
Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation
resolves10.1016/j.ejheart.2004.02.003
Effect of Carvedilol on Diastolic Function in Patients with Diastolic Heart Failure and Preserved Systolic Function. Results of the Swedish Doppler-Echocardiographic Study (SWEDIC)
resolves10.1093/eurjhf/hfr161
Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study
resolves10.1093/eurjhf/hfs141
Effects of Carvedilol on Heart Failure with Preserved Ejection Fraction: the Japanese Diastolic Heart Failure Study (J-DHF)
resolves10.1093/eurheartj/ehi386
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
resolves10.1016/j.jacc.2004.10.032
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?
resolves10.1016/S0195-668X(02)00743-1
Bisoprolol dose–response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)
resolves10.1161/01.CIR.94.11.2807
Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
resolves10.1016/j.jchf.2015.09.002
Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction
resolves10.1161/CIR.0b013e31829e8807
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
resolves10.1093/eurheartj/ehs104
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
resolves10.1016/S0140-6736(03)13800-7
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
resolves10.1016/S0140-6736(99)04440-2
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)
resolves10.1016/S0140-6736(98)11181-9
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
resolves10.1093/eurjhf/hfr020
Titration to Target Dose of Bisoprolol vs. Carvedilol in Elderly Patients with Heart Failure: The CIBIS-ELD Trial
resolves10.1016/j.amjcard.2008.07.045
Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)
resolves10.1093/eurjhf/hft134
Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term Registry
resolves10.1056/NEJMoa052475
Familial Sinus Bradycardia Associated with a Mutation in the Cardiac Pacemaker Channel
resolves10.1016/j.yjmcc.2008.04.013
Molecular basis of funny current (If) in normal and failing human heart
resolves10.1161/01.CIR.95.3.568
Characterization of the Hyperpolarization-Activated Current, I
<sub>f</sub>
, in Ventricular Myocytes From Human Failing Heart
resolves10.1161/01.CIR.97.1.55
Hyperpolarization-Activated Inward Current in Ventricular Myocytes From Normal and Failing Human Hearts
resolves10.1016/S0009-9236(98)90153-9
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers*
resolves10.1038/sj.bjp.0706998
Cellular mechanisms underlying the pharmacological induction of phosphenes
resolves10.1161/01.cir.0000048143.25023.87
Antianginal and Antiischemic Effects of Ivabradine, an I
<sub>f</sub>
Inhibitor, in Stable Angina
resolves10.1093/eurheartj/ehi586
Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
resolves10.2165/00003495-200767030-00005
Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris
resolves10.1093/eurheartj/ehn571
Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
resolves10.1016/S0140-6736(08)61170-8
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
resolves10.1016/j.ijcard.2010.10.125
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL
resolves10.1093/eurheartj/ehp358
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
resolves10.1056/NEJMoa1406430
Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
resolves10.1016/S0140-6736(10)61198-1
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
resolves10.1093/eurheartj/ehr343
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study
resolves10.1093/eurheartj/eht101
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
resolves10.1016/j.amjcard.2015.09.029
Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial)
resolves10.1093/eurheartj/ehs259
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
resolves10.1016/j.jacc.2013.07.027
Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients
resolves10.1093/eurheartj/ehr311
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
resolves10.1016/S0140-6736(10)61259-7
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
resolves10.1007/s00392-012-0467-8
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
resolves10.1056/NEJM199605233342101
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
resolves10.1161/01.CIR.0000035653.72855.BF
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
resolves10.1016/j.jacc.2012.01.020
Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?
resolves10.1093/eurheartj/ehv451
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
resolves10.1016/j.jchf.2013.11.002
Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation
resolves10.1136/heartjnl-2014-305482
Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials
resolves10.1016/j.jacc.2013.06.043
Effect of If-Channel Inhibition on Hemodynamic Status and Exercise Tolerance in Heart Failure With Preserved Ejection Fraction
resolves10.1161/CIRCULATIONAHA.115.017119
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction
resolves10.1016/j.jchf.2013.10.006
Developing Therapies for Heart Failure With Preserved Ejection Fraction
resolves10.1016/S0735-1097(96)00592-X
Tachycardia-Induced Cardiomyopathy: A Review of Animal Models and Clinical Studies
The 3 references without a DOI — listed, not checked
no DOI — not checkedUS Food and Drug Administration. Ivabradine: highlights of prescribing information. http://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2015/206143orig1s000lbl.Pdf. 2015. Accessed December 12 2015.
no DOI — not checkedEuropean Medicines Agency. Ivabradine: European public assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004187/WC500193961.pdf. 2015. Accessed December 12 2015.
no DOI — not checkedEuropean Medicines Agency. Ivabradine: European public assessment report - scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000597/WC500043587.pdf. Accessed December 12 2015.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1161/circulationaha.115.018094"><img src="https://citestamp.com/citestamped/10.1161/circulationaha.115.018094/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1161/circulationaha.115.018094)